newsfilter
← Earnings
Earnings Releases·

Definium Therapeutics — Third Quarter 2026 Earnings Summary

  • Cash and investments surged to $1.05 billion as of September 30, 2026, from $411.6 million at year-end 2025, with net loss narrowing to $51.0 million for the quarter from $67.3 million in 2025.
  • DT120 ODT achieved positive Phase 3 topline results in both GAD (Voyage and Panorama studies) and MDD (Emerge study), securing FDA Breakthrough Therapy designation for both indications.
  • Strategic outlook targets an NDA filing for DT120 ODT in the first half of 2027, with Phase 3 Ascend (MDD) and Haven (PTSD) studies expected to initiate or report data in 2027.
  • Share count increased to 136.9 million from 98.8 million in December 2025, while management confirmed cash reserves are sufficient to fund operations through 2030.
Company
DEFINIUM THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology